請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/50896
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 鍾孝文(Hsiao-Wen Chung) | |
dc.contributor.author | Yi-Ting Wu | en |
dc.contributor.author | 吳宜庭 | zh_TW |
dc.date.accessioned | 2021-06-15T13:05:03Z | - |
dc.date.available | 2016-08-02 | |
dc.date.copyright | 2016-08-02 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-07-05 | |
dc.identifier.citation | REFERENCE
[1] Kint, J. A. (1970). Fabry's disease: alpha-galactosidase deficiency. Science, 167(3922), 1268-1269. [2] Sweeley, C. C., & Klionsky, B. (1963). Fabry's disease: classification as a sphingolipidosis and partial characterization of a novel glycolipid. journal of Biological Chemistry, 238(9), PC3148-PC3150. [3] Brady, R. O., & Schiffmann, R. (2000). Clinical features of and recent advances in therapy for Fabry disease. Jama, 284(21), 2771-2775. [4] Scriver, C. R. (Ed.). (2001). The metabolic & molecular bases of inherited disease (Vol. 4). New York; Montreal: McGraw-Hill. [5] Linhart, A (2006) The heart in Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G (eds) Fabry disease: perspectives from 5 years of FOS, chap 20. Oxford PharmaGenesis, Oxford [6] Spada, M., Pagliardini, S., Yasuda, M., Tukel, T., Thiagarajan, G., Sakuraba, H., ... & Desnick, R. J. (2006). High incidence of later-onset Fabry disease revealed by newborn screening. The American Journal of Human Genetics, 79(1), 31-40. [7] Takenaka, T., Teraguchi, H., Yoshida, A., Taguchi, S., Ninomiya, K., Umekita, Y., ... & Yoshimitsu, M. (2008). Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. Journal of cardiology, 51(1), 50-59. [8] Desnick, R. J., Brady, R., Barranger, J., Collins, A. J., Germain, D. P., Goldman, M., ... & Wilcox, W. R. (2003). Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Annals of internal medicine, 138(4), 338-346. [9] Spada, M., Pagliardini, S., Yasuda, M., Tukel, T., Thiagarajan, G., Sakuraba, H., ... & Desnick, R. J. (2006). High incidence of later-onset Fabry disease revealed by newborn screening. The American Journal of Human Genetics, 79(1), 31-40.. [10] Lukas, J., Scalia, S., Eichler, S., Pockrandt, A. M., Dehn, N., Cozma, C., ... & Rolfs, A. (2016). Functional and Clinical Consequences of Novel α‐Galactosidase A Mutations in Fabry Disease. Human mutation, 37(1), 43-51. [11] Wittmann, J., Karg, E., Turi, S., Legnini, E., Wittmann, G., Giese, A. K., ... & Mühl, A. (2012). Newborn screening for lysosomal storage disorders in Hungary. In JIMD Reports-Case and Research Reports, 2012/3 (pp. 117-125). Springer Berlin Heidelberg. [12] Chien, Y. H., Lee, N. C., Chiang, S. C., Desnick, R. J., & Hwu, W. L. (2012). Fabry disease: incidence of the common later-onset alpha-galactosidase A IVS4+ 919G–> A mutation in Taiwanese newborns–superiority of DNA-based to enzyme-based newborn screening for common mutations. Mol Med, 18, 780-784. [13] Moran, P. R. (1982). A flow velocity zeugmatographic interlace for NMR imaging in humans. Magnetic resonance imaging, 1(4), 197-203. [14] Gatehouse, P. D., Keegan, J., Crowe, L. A., Masood, S., Mohiaddin, R. H., Kreitner, K. F., & Firmin, D. N. (2005). Applications of phase-contrast flow and velocity imaging in cardiovascular MRI. European radiology, 15(10), 2172-2184. [15] Stankovic, Z., Allen, B. D., Garcia, J., Jarvis, K. B., & Markl, M. (2014). 4D flow imaging with MRI. Cardiovascular diagnosis and therapy, 4(2), 173-192. [16] Chimenti, C., Pieroni, M., Morgante, E., Antuzzi, D., Russo, A., Russo, M. A., ... & Frustaci, A. (2004). Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation, 110(9), 1047-1053. [17] Ikari, Y., Kuwako, K., & Yamaguchi, T. (1992). Fabry's disease with complete atrioventricular block: histological evidence of involvement of the conduction system. British heart journal, 68(9), 323-325. [18] Spinelli, L., Pisani, A., Sabbatini, M., Petretta, M., Andreucci, M. V., Procaccini, D., ... & Cianciaruso, B. (2004). Enzyme replacement therapy with agalsidase β improves cardiac involvement in Fabry's disease. Clinical genetics, 66(2), 158-165. [19] Kals, J., Kampus, P., Kals, M., Zilmer, K., Kullisaar, T., Teesalu, R., ... & Zilmer, M. (2006). Impact of Oxidative Stress on Arterial Elasticity in Patients with Atherosclerosis*. American journal of hypertension, 19(9), 902-908. [20] Matsui, S., Murakami, E., Takeuchi, N., Hiramaru, Y., Kin, T., Maeda, N., ... & Saga, T. (1977). Cardiac manifestations of Fabry’s disease: Report of a case with pulrnonary regurgitation diagnosed on the basis of endomyocardial biopsy findings. Japanese circulation journal, 41(9), 1023-1036. [21] Linhart, A., Paleček, T., Bultas, J., Ferguson, J. J., Hrudová, J., Karetová, D., ... & Aschermann, M. (2000). New insights in cardiac structural changes in patients with Fabry’s disease. American heart journal, 139(6), 1101-1108. [22] Nishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., Guyton, R. A., ... & Sundt, T. M. (2014). 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 63(22), e57-e185. [23] Elliott, P. M., Kindler, H., Shah, J. S., Sachdev, B., Rimoldi, O. E., Thaman, R., ... & Camici, P. G. (2006). Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with α galactosidase A. Heart, 92(3), 357-360. [24] Dimitrow, P. P., Krzanowski, M., & Undas, A. (2005). Reduced coronary flow reserve in Anderson-Fabry disease measured by transthoracic Doppler echocardiography. Cardiovascular ultrasound, 3(1), 1. [25] Hope, T. A., Markl, M., Wigström, L., Alley, M. T., Miller, D. C., & Herfkens, R. J. (2007). Comparison of flow patterns in ascending aortic aneurysms and volunteers using four‐dimensional magnetic resonance velocity mapping. Journal of Magnetic Resonance Imaging, 26(6), 1471-1479. [26] Cheng, C. P., Parker, D., & Taylor, C. A. (2002). Quantification of wall shear stress in large blood vessels using Lagrangian interpolation functions with cine phase-contrast magnetic resonance imaging. Annals of biomedical engineering, 30(8), 1020-1032. [27] Morbiducci, U., Gallo, D., Cristofanelli, S., Ponzini, R., Deriu, M. A., Rizzo, G., & Steinman, D. A. (2015). A rational approach to defining principal axes of multidirectional wall shear stress in realistic vascular geometries, with application to the study of the influence of helical flow on wall shear stress directionality in aorta. Journal of biomechanics, 48(6), 899-906. [28] Thurberg, B. L., Fallon, J. T., Mitchell, R., Aretz, T., Gordon, R. E., & O'Callaghan, M. W. (2009). Cardiac microvascular pathology in fabry disease evaluation of endomyocardial biopsies before and after enzyme replacement therapy. Circulation, 119(19), 2561-2567. [29] Stalder, A. F., Russe, M. F., Frydrychowicz, A., Bock, J., Hennig, J., & Markl, M. (2008). Quantitative 2D and 3D phase contrast MRI: optimized analysis of blood flow and vessel wall parameters. Magnetic resonance in medicine, 60(5), 1218-1231. [30] Meierhofer, C., Schneider, E. P., Lyko, C., Hutter, A., Martinoff, S., Markl, M., ... & Fratz, S. (2013). Wall shear stress and flow patterns in the ascending aorta in patients with bicuspid aortic valves differ significantly from tricuspid aortic valves: a prospective study. Eur Heart J Cardiovasc Imaging, 14(8), 797-804. [31] Pieroni, M., Chimenti, C., Ricci, R., Sale, P., Russo, M. A., & Frustaci, A. (2003). Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation, 107(15), 1978-1984. [32] Hilz, M. J., Kolodny, E. H., Brys, M., Stemper, B., Haendl, T., & Marthol, H. (2004). Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. Journal of neurology, 251(5), 564-570. [33] Weidemann, F., Breunig, F., Beer, M., Sandstede, J., Störk, S., Voelker, W., ... & Strotmann, J. M. (2005). The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. European heart journal, 26(12), 1221-1227. [34] Koenig, W., Sund, M., Fröhlich, M., Fischer, H. G., Löwel, H., Döring, A., ... & Pepys, M. B. (1999). C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation, 99(2), 237-242. [35] Ku, D. N., Giddens, D. P., Zarins, C. K., & Glagov, S. (1985). Pulsatile flow and atherosclerosis in the human carotid bifurcation. Positive correlation between plaque location and low oscillating shear stress. Arteriosclerosis, thrombosis, and vascular biology, 5(3), 293-302. [36] Barker, A. J., Markl, M., Bürk, J., Lorenz, R., Bock, J., Bauer, S., ... & von Knobelsdorff-Brenkenhoff, F. (2012). Bicuspid aortic valve is associated with altered wall shear stress in the ascending aorta. Circulation: Cardiovascular Imaging, 5(4), 457-466. [37] Kröner, E. S., Lamb, H. J., Siebelink, H. M. J., Cannegieter, S. C., Boogaard, P. J., Wall, E. E., ... & Westenberg, J. J. (2014). Pulse wave velocity and flow in the carotid artery versus the aortic arch: effects of aging. Journal of Magnetic Resonance Imaging, 40(2), 287-293. [38] Mohiaddin, R. H., Firmin, D. N., & Longmore, D. B. (1993). Age-related changes of human aortic flow wave velocity measured noninvasively by magnetic resonance imaging. Journal of Applied Physiology, 74(1), 492-497. [39] van Ooij, P., Garcia, J., Potters, W. V., Malaisrie, S. C., Collins, J. D., Carr, J. C., ... & Barker, A. J. (2015). Age‐related changes in aortic 3D blood flow velocities and wall shear stress: Implications for the identification of altered hemodynamics in patients with aortic valve disease. Journal of Magnetic Resonance Imaging. [40] Redheuil, A., Yu, W. C., Mousseaux, E., Harouni, A. A., Kachenoura, N., Wu, C. O., ... & Lima, J. A. (2011). Age-related changes in aortic arch geometry: relationship with proximal aortic function and left ventricular mass and remodeling. Journal of the American College of Cardiology, 58(12), 1262-1270. [41] Craiem, D., Chironi, G., Redheuil, A., Casciaro, M., Mousseaux, E., Simon, A., & Armentano, R. L. (2012). Aging impact on thoracic aorta 3D morphometry in intermediate-risk subjects: looking beyond coronary arteries with non-contrast cardiac CT. Annals of biomedical engineering, 40(5), 1028-1038. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/50896 | - |
dc.description.abstract | 法布瑞氏症是ㄧ種先天性聯遺傳疾病,患者體內醣脂質(大多為GL-3)堆積於溶小體進而引發器官功能障礙,也因此有各種器官變異型,其中,心臟變異型為前三高的致死原因之一,患者無法早期得知症狀之嚴重程度導致錯過治療黃金時機。儘管目前已可藉由新生基因篩檢確診法布瑞氏症,但無法於適當時機進行治療,法布瑞氏症因此仍大幅提高患者之死亡率。
法布瑞氏症之發生率有逐漸增高的趨勢,許多基因變異陸續被認為是輕微的法布瑞氏症。早期的統計數字指出,約十一萬人有一人為法布瑞氏症患者,然而根據近期統計結果,台灣男性每八百七十五人就有一名為法布瑞氏症患者。於2015年台灣藥物銷售量統計,法布瑞氏症之基因治療藥物首度擠進前二十名,足可見法布瑞氏症之治療對於台灣醫療的重要性。 目前,早期診斷法布瑞氏症之變異仍屬於研究階段,如何藉由非侵入式影像診斷發現心臟變異,進而提早對患者進行治療是所有研究人員之理想目標。根據法布瑞氏症之病例報告,許多心臟變異型患者於早期有心臟瓣膜、血流、心肌、血管壁結構變異,最後會漸轉為心肌肥大及心肌纖維化而導致死亡,先前的研究利用超音波應變率變化、對比劑磁振造影T1-mapping於法布瑞氏患者心肌發現區域或廣泛異常,然而,尚未有人應用磁振造影相位對比技術之血流偵測於法布瑞氏患者之早期診斷,磁振造影之相位對比技術早已廣泛應用於血流之偵測,且於許多疾病都可見其分析成果。 根據我們的研究,初步使用磁振造影相位對比技術之血流偵測,其分析結果於三組(年輕控制組、年長控制組、法布瑞氏症患者)之相互比較有顯著差異,由這樣的結果可顯示磁振造影相位對比技術之血流偵測於早期診斷的初步應用價值。 | zh_TW |
dc.description.abstract | Fabry disease (FD) is an X chromosome-linked genetic disease, and would cause the lysosomal glycolipid accumulation so that leads to various organ dysfunctions. Of all the FD types, cardiac manifestation shows high mortality at the rank of top three. Actually, FD patients can be detected definitely by genetic test, but they can not notice the symptoms from mild organ defect. Therefore, the best time for specific therapy would be missed. The prevalence of FD is gradually increasing, because of raising amount of genetic defects are reported as mild FD. In previous study, the prevalence ratio of FD is 1:110,000, but in recent study of Taiwan, the male prevalence ratio is 1:875. The drug sale analysis data in 2015 in Taiwan indicates that FD genetic drug ranks into top twentieth at the first time. These present the importance of FD in Taiwan.
Nowadays, the study of FD early detect in cardiac manifestation is still in preliminary stage, and the ultimate goal of studies is using non-invasive tool to find the best timing to accept therapy and assess the effect of therapy. According to previous clinical reports, there is valvular dysfunction or flow, vessel wall and myocardium abnormality happened in FD patients in early stage. Some studies indicate impaired regional or global myocardial function from strain imaging (Doppler ultrasound) and T1 mapping (MRI). However, there is no study that explores flow abnormality by MR phase contrast (PC) imaging. In this study, we find significant difference among three groups (young controls, senior controls, and FD) by using PC-MRI flow analysis. It apparently displays the potential of PC-MRI flow analysis for FD early detect in cardiac manifestation. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T13:05:03Z (GMT). No. of bitstreams: 1 ntu-105-R03945021-1.pdf: 4008338 bytes, checksum: 07586558b758b5bf346bae4661a96ef9 (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | 口試委員會審定書 i
誌謝 ii 中文摘要 iii ABSTRACT iv CONTENTS v LIST OF FIGURES vii LIST OF TABLES ix Chapter 1 Introduction 1 1.1 Fabry disease 1 1.2 Motivation 3 1.3 Phase contrast 4 1.3.1 VENC 6 1.4 Cardiac circulation 7 1.5 Organization 8 Chapter 2 Hypothesis 15 2.1 Alteration of vessel wall elasticity and conduction cell 15 2.2 Valvular Dysfunction 16 2.3 Flow abnormality 17 Chapter 3 Materials and Method 18 3.1 Subjects 18 3.1.1 Healthy Volunteers 18 3.1.2 Clinical Volunteers 19 3.2 Data acquisition 19 3.2.1 Localizer 19 3.2.2 Flow techniques 20 3.3 Data processing 20 3.4 Aortic flow analysis 21 3.4.1 Flow parameters 21 3.4.2 Mean velocity 22 3.4.3 Retrograde flow 22 3.4.4 Wall shear stress 23 3.5 Statistics 24 Chapter 4 Results 35 4.1 Outliers exclusion 35 4.2 The result of PC-MRI flow analysis 36 4.2.1 Young control and FD 36 4.2.2 Senior control and FD 37 4.2.3 Regional WSS between senior control and FD 38 4.3 Flow parameters 39 4.4 Mean velocity 39 4.5 Wall shear stress 40 Chapter 5 Discussion and conclusion 82 5.1 Discussion 82 5.1.1 Senior control and FD analysis result 82 5.1.2 Limitation 84 5.2 Conclusion 85 REFERENCE 88 | |
dc.language.iso | en | |
dc.title | 相位磁振造影偵測動脈血流之異常應用於法布瑞氏症心臟變異型之患者 | zh_TW |
dc.title | MR phase contrast detection of aortic flow abnormality in Fabry disease with cardiac manifestation | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 黃騰毅(Teng-Yi Huang),彭旭霞(Hsu-Hsia Peng),王昭穎(Chao-Ying Wang),蔡尚岳(Shang-Yueh Tsai) | |
dc.subject.keyword | 法布瑞氏症,心臟變異型,相位對比磁共振影像,血流偵測, | zh_TW |
dc.subject.keyword | Fabry disease,cardiac manifestation,phase contrast imaging,flow analysis, | en |
dc.relation.page | 93 | |
dc.identifier.doi | 10.6342/NTU201600661 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2016-07-06 | |
dc.contributor.author-college | 電機資訊學院 | zh_TW |
dc.contributor.author-dept | 生醫電子與資訊學研究所 | zh_TW |
顯示於系所單位: | 生醫電子與資訊學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-1.pdf 目前未授權公開取用 | 3.91 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。